Amgen 145 Study Shows No Difference In Risk Of Death In Aranesp-Treated Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Outcome could help to stabilize the use of erythropoiesis-stimulating agents in anemia patients in the oncology setting.
You may also be interested in...
EPO Aggressive Dosing May Be Curtailed By New Black Box Warning
Labeling for Amgen’s Aranesp and Epogen and Johnson & Johnson’s Procrit updated March 9 to include a black box warning on risk of mortality.
Amgen “Dear Doctor” Letter Warns Of Risk Of Death Associated With Aranesp
Letter follows release of data in patients receiving darbepoetin alfa who have anemia that is not due to concurrent chemotherapy, an off-label use.
Epoetin Alfa Increases Cardiovascular Risks When Targeting High Hemoglobin Levels, J&J Study Finds
Patients with chronic kidney disease, when treated with a more aggressive dose of Procrit, had a higher risk but no incremental improvement in quality of life.